Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.32 |
| ▸ | PARK7 | Q99497 | 1/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22245635 | 0.82 | CHRM5 (0.33) | PARK7CHRM5 | |
| SCHEMBL2148307 | 0.82 | CHRM5 (0.33) | PARK7CHRM5 | |
| SCHEMBL2299018 | 0.80 | CHRM5 (0.33) | PARK7CHRM5 | |
| SCHEMBL2148389 | 0.78 | POLB (0.35) | PARK7CHRM5POLBMAPTNPC1 | |
| SCHEMBL2297152 | 0.76 | POLB (0.35) | PARK7CHRM5POLBMAPTNPC1 | |
| SCHEMBL29524136 | 0.75 | POLB (0.36) | PARK7CHRM5POLBMAPTNPC1 | |
| SCHEMBL29778248 | 0.74 | POLB (0.32) | PARK7CHRM5POLB | |
| SCHEMBL2148315 | 0.74 | POLB (0.32) | PARK7CHRM5POLB | |
| SCHEMBL2292667 | 0.72 | POLB (0.32) | PARK7CHRM5POLB | |
| SCHEMBL5926162 | 0.71 | EGFR (0.32) | POLBHPGDMAPTNPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110162227-A1 | PYRROLOBENZODIAZEPINES | SPIROGEN LIMITED (GB) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110162227-A1 | PYRROLOBENZODIAZEPINES | GRIN2C, ZKSCAN2, ZRANB2 | PFKFB3 2475/4885PARK7 350/4885CHRM5 1046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.